Latest Von Willebrand disease Stories
MONTREAL, April 16, 2013 /PRNewswire/ -- The global bleeding disorders community will come together on April 17 to mark World Hemophilia Day. This event takes on a special significance as it coincides with the 50(th) anniversary of the World Federation of Hemophilia (WFH). To commemorate its 50(th) anniversary, the WFH has launched a hemophilia awareness video entitled The Journey Begins. It explores the origins of the WFH and the inspired role that Frank Schnabel played in bringing...
CSL Behring initiates first "installment" of renewed 3-year commitment to WFH to donate coagulation factor to the WFH Global Alliance for Progress program KING OF PRUSSIA, Pa., April 3, 2013 /PRNewswire/ -- As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Hemophilia Day this month. The medicine will be used in treating patients in...
WebTracker-Hemophilia Software Used as the National Information Infrastructure Given New Brand Name HemaGlobal for Overseas Markets SAN FRANCISCO, April 2, 2013 /PRNewswire/ -- GZS, Inc., a leader in developing disease-specific and condition-specific Electronic Medical Records/Electronic Health Records (EMR/EHR) and patient registry software solutions, has announced the worldwide release of the WebTracker-Hemophilia((TM)) EHR patient registry solution used under the new brand name...
BEDFORD, Mass., Feb. 5, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar von Willebrand Factor (VWF) assay panel as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. The CE IVD Mark allows IL to commence distribution of the product in the European Union and other international territories. The fully automated HemosIL AcuStar VWF assay panel, designed exclusively for use on...
KING OF PRUSSIA, Pa., Jan. 30, 2013 /PRNewswire/ -- CSL Behring announced today that it has awarded $78,750 in Local Empowerment for Advocacy Development (LEAD) grants to patient advocacy organizations in New York and Ohio, and to the American Plasma Users Coalition (APLUS). LEAD grants are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or creating a new one. (Logo:...
KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the pivotal pediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years). The study site for this first enrollment is the Czech Republic. "CSL continues to advance at a very encouraging rate with...
KING OF PRUSSIA, Pa., Aug. 1, 2012 /PRNewswire/ -- CSL Behring announced today that it has awarded six patient advocacy organizations in the U.S. with Local Empowerment for Advocacy Development (LEAD) grants totaling nearly $70,000. LEAD grants are awarded semiannually and are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or developing a new one. (Logo:...
KING OF PRUSSIA, Pa., July 11, 2012 /PRNewswire/ -- Findings of a first-of-its-kind study of women with von Willebrand disease (VWD) show that current postpartum treatment strategies do not increase levels of von Willebrand factor (VWF) to normal range or even to the levels of women with milder, untreated VWD. VWF is a blood protein important for preventing postpartum hemorrhage. Results of this nationwide study are being presented at the World Federation of Hemophilia...
Strategic focus and robust portfolio of services continue to create record distribution trend for specialty biotech distributor BDI Pharma. Columbia, SC (PRWEB) June 21, 2012 BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, after finishing the previous calendar year with a record level of distribution in anti-hemophilic factor (AHF), announced today that through the first five (5) months of 2012, the company’s distribution is tracking...
KING OF PRUSSIA, Pa., June 8, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital factor IX deficiency (hemophilia B). The designation includes routine...
